Trial Profile
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Acronyms E.C.L.I.P.S.E.; ECLIPSE
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Aug 2018 Results of a post-hoc analysis presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
- 12 Dec 2017 Outcomes of a model developed using 12-month data from the controlled registration study (ICL670A108) and applied to both deferasirox film-coated tablet (FCT) and dispersible tablet (DT) arms of ECLIPSE trial for predicting serum ferritin levels in these patients if they continued both arms for 6-12 months, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 25 Jun 2017 Results of post hoc analysis of Eclipse trial presented at the 22nd Congress of the European Haematology Association